Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Known antihypertensive drug introduced by Santen for glaucoma in Japan

Dec. 21, 2001

Novartis Ophthalmics and Kissei enter license option agreement for novel glaucoma agent

Dec. 20, 2001

ISTA finalizes data collection from Vitrase phase III trials

Dec. 18, 2001

Alcon and Angiotech terminate ophthalmic R&D collaboration

Nov. 27, 2001

Novel optic nerve-regenerating growth factor identified as potential glaucoma therapeutic

Nov. 27, 2001

New product significantly reduces the risk of AMD

Nov. 26, 2001

Alcon identifies several related series of antiglaucoma agents

Nov. 22, 2001

Positive opinion issued for Lumigan by CPMP

Nov. 21, 2001

Launch of Xalcom/Xalacom begins in Europe

Nov. 20, 2001

Six-month results presented for CAT-152 following glaucoma and cataract surgery

Nov. 16, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...